Cocrystal Pharma (COCP) Projected to Post Quarterly Earnings on Thursday

Cocrystal Pharma (NASDAQ:COCP) will likely be issuing its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.17) per share and revenue of $0.2250 million for the quarter.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, analysts expect Cocrystal Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cocrystal Pharma Trading Up 4.1%

Shares of Cocrystal Pharma stock opened at $1.02 on Thursday. The firm has a fifty day simple moving average of $0.99 and a 200-day simple moving average of $1.10. The stock has a market capitalization of $14.07 million, a price-to-earnings ratio of -1.40 and a beta of 1.43. Cocrystal Pharma has a 1-year low of $0.76 and a 1-year high of $2.67.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cocrystal Pharma presently has an average rating of “Sell”.

Institutional Trading of Cocrystal Pharma

A hedge fund recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.